Paradigm Biopharmaceuticals Ltd News

Paradigm Biopharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Apr 29 19:54 ET

Paradigm Biopharmaceuticals Ltd: Type D Response Submitted and Received by the US FDA

Apr 18 18:36 ET

Paradigm Biopharmaceuticals Ltd: PAR to present at NWR Healthcare Conference

Mar 19 23:45 ET

Paradigm Biopharmaceuticals Ltd: Change of Director's Interest Notice

Mar 7 21:18 ET

Paradigm Biopharmaceuticals Ltd: Change of Director's Interest Notice

Mar 7 21:17 ET

Paradigm Biopharmaceuticals Ltd: Final Director's Interest Notice

Mar 5 17:27 ET

Paradigm Biopharmaceuticals Ltd: Initial Director's Interest Notice

Mar 3 19:20 ET

Paradigm Biopharmaceuticals Ltd: PAR Employee Performance Rights Plan Issue

Feb 28 18:17 ET

Paradigm Biopharmaceuticals Ltd: PAR Appoints Business Development Consultant

Feb 9 00:45 ET

Paradigm Biopharmaceuticals Ltd: Primary Endpoint Achieved in Phase 2 MPS VI Trial

Feb 8 17:04 ET

Paradigm Biopharmaceuticals Ltd: Paradigm Receives $7.36m R&D Tax Incentive Refund

Feb 6 17:14 ET

Paradigm Biopharmaceuticals Ltd: Quarterly Activities/Appendix 4C Cash Flow Report

Jan 30 16:48 ET

Paradigm Biopharmaceuticals Ltd: PAR Selected for Major OA Conference Presentations

Jan 29 17:12 ET

Paradigm Biopharmaceuticals Ltd: Notice of release of escrowed securities

Jan 15 02:46 ET

Paradigm Biopharmaceuticals Ltd: Change of Director's Interest Notice - Fisher

Nov 30, 2023 19:04 ET

Paradigm Biopharmaceuticals Ltd: Change of Director's Interest Notice - Rennie

Nov 29, 2023 22:50 ET

Paradigm Biopharmaceuticals Ltd: 2023 AGM Chairman Address

Nov 28, 2023 16:39 ET

Paradigm Biopharmaceuticals Ltd: Security Class Reinstatement to Quotation PARO

Nov 27, 2023 17:22 ET

Paradigm Biopharmaceuticals Ltd: Listing of Options - Top 20 Holders and Distribution Reports

Nov 26, 2023 20:57 ET

Paradigm Biopharmaceuticals Ltd: Security Class Suspension from Quotation PARO

Nov 20, 2023 16:49 ET